Taxanes in combined-modality therapy for solid tumors

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

The taxanes, paclitaxel and docetaxel, are novel antimitotic agents that are under extensive investigation in clinical trials in patients with various solid tumors. The taxanes have demonstrated significant activity against many solid tumors as single agents and in combination with other chemotherapeutic agents. In addition, paclitaxel and docetaxel arrest cells at the G2/M phase of the cell cycle, which is the most radiosensitive phase. Numerous clinical trials have assessed paclitaxel-based chemoradiation therapy in a variety of tumor types, including non-small-cell lung cancer, small-cell lung cancer, head and neck cancers, esophageal cancer, brain tumors, pancreatic and gastric tumors, and locally advanced breast cancer. Fewer clinical trials have assessed docetaxel plus radiation therapy in these tumor types. This review highlights recent clinical trials of the taxanes in combination with radiation therapy for solid tumors.

Original languageEnglish (US)
Pages (from-to)23-38
Number of pages16
JournalOncology
Volume13
Issue number10 SUPPL. 5
StatePublished - 1999

Fingerprint

Taxoids
Combined Modality Therapy
docetaxel
Paclitaxel
Clinical Trials
Neoplasms
Head and Neck Neoplasms
Brain Neoplasms
Radiotherapy
Antimitotic Agents
G2 Phase
Small Cell Lung Carcinoma
Esophageal Neoplasms
Non-Small Cell Lung Carcinoma
Cell Division
Stomach Neoplasms
Cell Cycle
Breast Neoplasms

ASJC Scopus subject areas

  • Oncology

Cite this

Taxanes in combined-modality therapy for solid tumors. / Choy, Hak.

In: Oncology, Vol. 13, No. 10 SUPPL. 5, 1999, p. 23-38.

Research output: Contribution to journalArticle

Choy, H 1999, 'Taxanes in combined-modality therapy for solid tumors', Oncology, vol. 13, no. 10 SUPPL. 5, pp. 23-38.
Choy, Hak. / Taxanes in combined-modality therapy for solid tumors. In: Oncology. 1999 ; Vol. 13, No. 10 SUPPL. 5. pp. 23-38.
@article{ce8f01be34f04e1380f22cdd01726cd7,
title = "Taxanes in combined-modality therapy for solid tumors",
abstract = "The taxanes, paclitaxel and docetaxel, are novel antimitotic agents that are under extensive investigation in clinical trials in patients with various solid tumors. The taxanes have demonstrated significant activity against many solid tumors as single agents and in combination with other chemotherapeutic agents. In addition, paclitaxel and docetaxel arrest cells at the G2/M phase of the cell cycle, which is the most radiosensitive phase. Numerous clinical trials have assessed paclitaxel-based chemoradiation therapy in a variety of tumor types, including non-small-cell lung cancer, small-cell lung cancer, head and neck cancers, esophageal cancer, brain tumors, pancreatic and gastric tumors, and locally advanced breast cancer. Fewer clinical trials have assessed docetaxel plus radiation therapy in these tumor types. This review highlights recent clinical trials of the taxanes in combination with radiation therapy for solid tumors.",
author = "Hak Choy",
year = "1999",
language = "English (US)",
volume = "13",
pages = "23--38",
journal = "Oncology",
issn = "0890-9091",
publisher = "UBM Medica Healthcare Publications",
number = "10 SUPPL. 5",

}

TY - JOUR

T1 - Taxanes in combined-modality therapy for solid tumors

AU - Choy, Hak

PY - 1999

Y1 - 1999

N2 - The taxanes, paclitaxel and docetaxel, are novel antimitotic agents that are under extensive investigation in clinical trials in patients with various solid tumors. The taxanes have demonstrated significant activity against many solid tumors as single agents and in combination with other chemotherapeutic agents. In addition, paclitaxel and docetaxel arrest cells at the G2/M phase of the cell cycle, which is the most radiosensitive phase. Numerous clinical trials have assessed paclitaxel-based chemoradiation therapy in a variety of tumor types, including non-small-cell lung cancer, small-cell lung cancer, head and neck cancers, esophageal cancer, brain tumors, pancreatic and gastric tumors, and locally advanced breast cancer. Fewer clinical trials have assessed docetaxel plus radiation therapy in these tumor types. This review highlights recent clinical trials of the taxanes in combination with radiation therapy for solid tumors.

AB - The taxanes, paclitaxel and docetaxel, are novel antimitotic agents that are under extensive investigation in clinical trials in patients with various solid tumors. The taxanes have demonstrated significant activity against many solid tumors as single agents and in combination with other chemotherapeutic agents. In addition, paclitaxel and docetaxel arrest cells at the G2/M phase of the cell cycle, which is the most radiosensitive phase. Numerous clinical trials have assessed paclitaxel-based chemoradiation therapy in a variety of tumor types, including non-small-cell lung cancer, small-cell lung cancer, head and neck cancers, esophageal cancer, brain tumors, pancreatic and gastric tumors, and locally advanced breast cancer. Fewer clinical trials have assessed docetaxel plus radiation therapy in these tumor types. This review highlights recent clinical trials of the taxanes in combination with radiation therapy for solid tumors.

UR - http://www.scopus.com/inward/record.url?scp=0033212570&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033212570&partnerID=8YFLogxK

M3 - Article

C2 - 10550824

AN - SCOPUS:0033212570

VL - 13

SP - 23

EP - 38

JO - Oncology

JF - Oncology

SN - 0890-9091

IS - 10 SUPPL. 5

ER -